Cytokines and atherogenesis
Cytokines are defined as soluble (g1yco)proteins that are released by cells to regulate cellular functions [2] . In general, these molecules act in the nano-to picomolar concentration range to regulate cellular responses. Cytokines are themselves grouped into four categories: interleukins, interferons, colony-stimulating factors, and peptide growth factors. Endothelial cells, vascular-smoothmuscle cells, mononuclear cells/tissue macrophages, lymphocytes and platelets can all be induced to elaborate a variety of cytokines, and these molecules ultimately promote endothelial-and vascular-smooth-muscle-cell migration, vascularsmooth-muscle-cell replication, and monocyte activation. Adhesion to matrix molecules, adhesion to other cells, or exposure to cytokines themselves can lead to the elaboration of cytokines by the cells involved in atherogenesis. Cytokines, in turn, exert their effects on cell migration and on replication by inducing cells to modify the matrix, by modulating the expression of cellular adhesion molecules (see The historical context within which cytokine biology has been defined, that is, inflammation, leads to an appreciation of the mechanistic underpinning associating atherosclerosis and inflammation, and to a clearer understanding of the regulation of inflammatory-cell responses in atherogenesis [ 3 ] . The mechanism by which cytokine growth factors, in particular, induce cell replication has been well-studied. Growth factors bind to their specific growth-factor receptors localized on the surface of the cell responding to that factor. These receptors commonly span the cell-surface membrane and are noncovalently associated with one of several coupling protins, including guanine-nucleotide-binding (G) proteins and tyrosine kinases, on the inner surface of the membrane. Through common responses supported by these coupling proteins, the surface-binding signal is transduced to increase the intracellular calcium concentration and to activate protein kinases. These latter events ultimately lead to the activation of transcription factors that induce the genomic response( s) that support cell replication.
Vascular-cell replication also depends critically on the modulation of the matrix. Matrix
Volume 2 I modification occurs as a consequence of the elaboration of tissue metalloproteases (matrixins) by vascular cells [4] , a process that is induced by epidermal GF and by fibroblast GF [5] . By contrast, transforming growth factor-/3 shows an anti-proliferative action as a consequence of the repression of matrixin activity and the reciprocal induction of an inhibitor of tissue metalloprotease [6].
The expression of adhesion molecules that promote the association of blood cells with vascular cells is yet another effect of cytokine stimulation that is critical for atherogenesis. These adhesion molecules promote the adhesion of vascular cells to the matrix, as well as promoting adhesion to the endothelium and emigration from the blood-vessel lumen into the vessel wall, similarly to their role in inflammation. The complexity of this group of molecules and of the regulation of their expression warrants detailed discussion.
Adhesion molecules and atherogenesis
Blood and vascular-cell-adhesion molecules are divided into three classes: the selectins, the integrins, and the immunoglobulin superfamily. Celladhesion molecules in each of these classes that are believed to be important in atherogenesis are listed below: Integrins on activated leukocytes interact with endothelial counter-receptors that are members of the immunoglobulin superfamily. Each of these proteins contains a series of immunoglobulin-like domains of 90-100 amino acids [ 121. LFA-1 binds to ICAM-1 and 2; Mac-1 binds to ICAM-1, but not to ICAM-2; and VLA-4 binds to vascular-cell adhesion molecule 1 (VCAM-1). In addition, another member of the immunoglobulin superfamily, PECAM-1, serves as its own counter-receptor and facilitates early adhesion of mononuclear cells to endothelial cells [ 13, 141. The interactions among these adhesion molecules that result in leukocyte adhesion, diapedesis and emigration have been identified recently [ 151. Under resting conditions, leukocytes do not adhere to endothelial cells; however, in the presence of inflammatory mediators, a two-phased response is noted. Firstly, within 6 h of exposure to acute mediators, such as histamine or thrombin, initial adhesion or rolling is observed, mediated by the selectins and, possibly, by PECAM-1. Cytokineinduced (interleukin-1, interferon-a) tight adhesion occurs at 6-48 h as a consequence of the interaction between integrins and immunoglobulin-like molecules. The precise mechanism(s) by which these 657 ~91. [25] .
Given the affinity of apoprotein(a) for fibrin(ogen) and the co-localization of fibrin(ogen) and lipro(apo)protein(a) in atheromatous plaques [26, 271, we hypothesized that lipoprotein(a) is atherogenic not only because it is a ligand for the scavenger pathway after oxidation [28] , but also as a result of its impairing the clearance of fibrin(ogen) from atheromatous lesions [29] . (Fibrin[ogen] and its proteolytic degradation fragments in the vessel wall show a variety of atherogenic properties, including the induction of vascular-smooth-musclecell replication, endothelial migration, and monocyte chemotaxis [29] .) This hypothesis was tested by evaluating the ability of lipoprotein(a) to attenuate cellular clearance of fibrin(ogen). As Altieri and colleagues showed [30] and we confirmed, fibrin(ogen) binds to activated human monocytes through the integrin Mac-1 (CD 1 1 b/CD 18). W e also found, however, that the interaction of this pluripotent integrin with fibrin(ogen) leads to the internalization of the ligand-receptor complex, with subsequent proteolysis of the ligand [ 3 I]. W e believe that this unique Volume 21 mechanism of cellular fibrinolysis is probably responsible for the comparatively slow clearance of vascular thrombi during recanalization, as distinct from the rapid plasmin-mediated fibrinolysis. Finally, we showed that lipoprotein(a), when complexed with fibrin(ogen), impaired the uptake and degradation of fibrin(ogen) by the Mac-1 pathway [31] . Very recently, we have taken these observations one step further and shown that the lipoprotein(a)-fibrin(ogen) complex induces the expression of the adhesion molecules E-selectin and ICAM-1 on the endothelial cell. Thus, this lipoprotein has a variety of properties that support atherogenesis by mechanisms that involve the molecules that govern vascular-cell interactions that, in turn, sustain the atherogenic process.
These observations illustrate the molecular mechanisms that govern the complex interactions among the vascular cells and blood cells that are involved in atherogenesis. The induction, regulation and modulation of these interactions between cells, and between cells and vascular matrix, represent potential targets for pharmacologic and, perhaps in the future, genetic intervention.
